Literature DB >> 14624369

Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen.

Alan L Landay1, John Spritzler, Harold Kessler, Donna Mildvan, Minya Pu, Larry Fox, Dorothy O'Neil, Barbara Schock, Daniel Kuritzkes, Michael M Lederman.   

Abstract

We compared immune restoration in patients who suppressed human immunodeficiency virus type 1 replication after treatment with a protease inhibitor (PI) plus nevirapine or with 3 nucleoside reverse-transcriptase inhibitors (NRTIs) plus nevirapine. Changes in total and memory CD4 and CD8 cells were similar in the groups, as were decreases in immune activation (e.g., CD38 and HLA-DR) and increases in CD28 expression. Increases in naive CD4 and CD8 cells tended to be greater in the NRTI-treated group, with differences in naive CD4 cells significant at weeks 8 and 12 (P<.05) but not at week 48. Lymphocyte apoptosis decreased in both groups, but the week-1 decrease was greater in the PI-treated group (P<.02). Lymphocyte proliferation and skin-test responses were comparable. We find little evidence for differences in the major direct immunologic effect of PI versus NRTI regimens and propose that effects observed elsewhere were indirect, mediated through antiviral activity or adaptation of the virus to selection pressure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14624369     DOI: 10.1086/379041

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor.

Authors:  Joel G R Weaver; Agathe Tarze; Tia C Moffat; Morgane Lebras; Aurelien Deniaud; Catherine Brenner; Gary D Bren; Mario Y Morin; Barbara N Phenix; Li Dong; Susan X Jiang; Valerie L Sim; Bogdan Zurakowski; Jessica Lallier; Heather Hardin; Peter Wettstein; Rolf P G van Heeswijk; Andre Douen; Romano T Kroemer; Sheng T Hou; Steffany A L Bennett; David H Lynch; Guido Kroemer; Andrew D Badley
Journal:  J Clin Invest       Date:  2005-07       Impact factor: 14.808

Review 2.  HIV protease inhibitors impact on apoptosis.

Authors:  Stacey A Rizza; Andrew D Badley
Journal:  Med Chem       Date:  2008-01       Impact factor: 2.745

3.  AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics.

Authors:  Marlene Smurzynski; Ann C Collier; Susan L Koletar; Ronald J Bosch; Kunling Wu; Barbara Bastow; Constance A Benson
Journal:  HIV Clin Trials       Date:  2008 Jul-Aug

4.  No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.

Authors:  Heather J Ribaudo; Constance A Benson; Yu Zheng; Susan L Koletar; Ann C Collier; Judith J Lok; Marlene Smurzynski; Ronald J Bosch; Barbara Bastow; Jeffrey T Schouten
Journal:  Clin Infect Dis       Date:  2011-04-01       Impact factor: 9.079

5.  Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis.

Authors:  Supriya Krishnan; Jeffrey T Schouten; Denise L Jacobson; Constance A Benson; Ann C Collier; Susan L Koletar; Jorge Santana; Fred R Sattler; Ronald Mitsuyasu
Journal:  Oncology       Date:  2011-05-23       Impact factor: 2.935

6.  CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies.

Authors:  Katherine Tassiopoulos; Alan Landay; Ann C Collier; Elizabeth Connick; Steven G Deeks; Peter Hunt; Dorothy E Lewis; Cara Wilson; Ronald Bosch
Journal:  J Infect Dis       Date:  2012-03-23       Impact factor: 5.226

7.  HIV peripheral neuropathy progression: protection with glucose-lowering drugs?

Authors:  Scott R Evans; Anthony J Lee; Ronald J Ellis; Huichao Chen; Kunling Wu; Ronald J Bosch; David B Clifford
Journal:  J Neurovirol       Date:  2012-07-18       Impact factor: 2.643

8.  Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV.

Authors:  Timothy W Schacker; Ronald J Bosch; Kara Bennett; Richard Pollard; Gregory K Robbins; Ann C Collier; Roy M Gulick; John Spritzler; Donna Mildvan
Journal:  J Acquir Immune Defic Syndr       Date:  2010-05-01       Impact factor: 3.731

9.  Intracellular Casp8p41 content is inversely associated with CD4 T cell count.

Authors:  Nathan W Cummins; Wei Jiang; John McGinty; Gary D Bren; Ronald J Bosch; Alan Landay; Steven G Deeks; Jeffrey N Martin; Daniel Douek; Michael M Lederman; Jason Brenchley; Andrew D Badley
Journal:  J Infect Dis       Date:  2010-08-15       Impact factor: 5.226

10.  The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy.

Authors:  Judith J Lok; Peter W Hunt; Ann C Collier; Constance A Benson; Mallory D Witt; Amneris E Luque; Steven G Deeks; Ronald J Bosch
Journal:  AIDS       Date:  2013-08-24       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.